A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1.

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...